SNY - French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication For About $2.2B | Benzinga
Sanofi SA (NASDAQ:SNY) has agreed to acquire assets and liabilities associated with Inhibrx Inc’s (NASDAQ:INBX) INBRX-101, an optimized, recombinant alpha-1 antitrypsin augmentation therapy currently in a registrational trial for alpha-1 antitrypsin deficiency.
Immediately before the closing of the merger, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109, Inhibrx’s non-101 discovery pipeline, and its corporate infrastructure, will be spun out from Inhibrx into a new publicly traded company, Inhibrx Biosciences Inc (New Inhibrx).
Under the terms of the agreement, Sanofi will acquire all outstanding shares of Inhibrx through a merger for $30.00 per share ...